IDXX vs. SNN: IDEXX Laboratories vs. Smith & Nephew Stock Comparison

Company Profile

IDEXX Laboratories (IDXX) and Smith & Nephew (SNN) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

IDEXX Laboratories (IDXX) trades as ordinary local shares, while Smith & Nephew (SNN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

IDEXX Laboratories (IDXX) has an aggressive beta of 1.44, indicating higher sensitivity to broad-market moves, while Smith & Nephew (SNN) is defensive at 0.49 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

IDEXX Laboratories (IDXX) at 68.93% clears its industry range for ROE, a sharper capital-efficiency signal than Smith & Nephew (SNN) at 11.85%, which is closer to a typical peer reading.

For every dollar of sales, both IDEXX Laboratories (IDXX) at 25.36% and Smith & Nephew (SNN) at 10.08% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both IDEXX Laboratories (IDXX) at 33.14% and Smith & Nephew (SNN) at 14.47% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both IDEXX Laboratories (IDXX) at 10.42% and Smith & Nephew (SNN) at 6.09% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Smith & Nephew (SNN) at 52.34% sits in the top EPS growth quartile, while IDEXX Laboratories (IDXX) at 22.59% is closer to the peer norm — faster per-share earnings growth for SNN.

Growth Metrics

Financial Strength

Smith & Nephew (SNN) at 2.14 keeps current ratio within its industry’s typical mid-range, while IDEXX Laboratories (IDXX) at 1.19 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IDXX.

Both IDEXX Laboratories (IDXX) at 0.52 and Smith & Nephew (SNN) at 0.73 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

IDEXX Laboratories (IDXX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a yield of 1.24%, ranking against industry peers normally.

IDEXX Laboratories (IDXX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a payout of 53.20%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both IDEXX Laboratories (IDXX) at 45.56 and Smith & Nephew (SNN) at 21.19 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Smith & Nephew (SNN) at 2.07 prices around its industry’s typical P/S ratio, while IDEXX Laboratories (IDXX) at 11.42 clears its benchmark range — IDXX looks notably rich on sales.

Measured against book value, both IDEXX Laboratories (IDXX) at 28.50 and Smith & Nephew (SNN) at 12.80 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics